Cipla launches RT-PCR test kit ‘ViraGen’ in India partnership with Ubio Biotech

By: |
May 20, 2021 11:02 AM

Cipla will launch ViraGen test kit in the country in partnership with Ubio Biotechnology Systems, the company stated.

Shares of Cipla closed at Rs 946.40 per scrip on BSE, down 0.29 per cent from its previous close.Shares of Cipla closed at Rs 946.40 per scrip on BSE, down 0.29 per cent from its previous close.

Drug major Cipla on Thursday announced the commercialisation of its RT-PCR test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems.

“This launch will help address the current testing services and capacity issues while reaffirming the company’s ongoing expansion in the diagnostic space,” Cipla said in a regulatory filing.

Cipla will launch ViraGen test kit in the country in partnership with Ubio Biotechnology Systems, the company stated.

The company will commence supply of the COVID-19 virus detection kit from May 25, 2021.

Umang Vohra, MD and Global CEO, Cipla, said, ?Cipla has been working relentlessly to ensure accessibility to treatments in this fight against COVID-19. Guided by our core purpose of ‘Caring for Life’, this partnership will enable us to reach out to more people across the country at a crucial time like now.

ViraGen is Cipla’s third offering in the COVID-19 testing segment.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Haryana extends lockdown till June 28, announces more relaxations
2Weekend Covid curfew lifted from eight districts in Jammu and Kashmir
3Public parks, gardens to open in Delhi from Monday, outdoor yoga activities to be allowed: DDMA